| Authors: |
Slarve MJ; Immunology and Immune Therapeutics Department, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, NTT 6419, Los Angeles, CCA 90033A, USA. matt.slarve@gmail.com., Tkaczyk C; Early Infectious Disease, Biopharmaceuticals Business Unit, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Doyle MP; Early Infectious Disease, Biopharmaceuticals Business Unit, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Break TJ; Early Infectious Disease, Biopharmaceuticals Business Unit, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Smith AB; Early Infectious Disease, Biopharmaceuticals Business Unit, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Alter G; Early Infectious Disease, Biopharmaceuticals Business Unit, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Luna B; Immunology and Immune Therapeutics Department, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, NTT 6419, Los Angeles, CCA 90033A, USA., Spellberg B; Los Angeles General Medical Center, Los Angeles, CA, USA., DiGiandomenico A; Early Infectious Disease, Biopharmaceuticals Business Unit, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA. antonio.digiandomenico@astrazeneca.com. |
